As a life-long pet owner, Ive owned pets that have suffered from improper diagnosis on drug resistant infections and Im convinced LexaGenes technology can significantly improve the speed and quality of care veterinarians are able to provide at the point of care. In particular, Meridian announced that on February 8, 2022 and February 18, 2022, Meridian Holdings completed the purchase of 18,500,000 units of the Issuer (the "Units") on a private placement basis at a price of C$0.35 per Unit (the "Unit Purchases") for aggregate consideration of C$6,475,000. This should have a meaningful impact on this aspect of veterinary care.. Proactive has always been a forward looking and enthusiastic technology adopter. Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS. New Bitcoin ETFs Now? Accelerate is an in-depth exploration of the science, ethos and implications of near-future transportation methods. All rights reserved. Proactive news team spans the worlds key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. Copyright Proactive Group Holdings Inc, 2023. LexaGene announces that it has signed a statement of work with the same biopharma company that purchased a System last week. Meridian Holding LLC was founded in 2007. These audience insights are used to make our website more relevant. LexaGene Holdings Announces Results of February 8, 2023 Annual General Meeting, LexaGene Provides Update on BioPharma Sector, LexaGenes MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers, BioPharma Engages LexaGene in Second Feasibility Study, LexaGene Holdings Proposes to Amend Warrants Terms, LexaGene Successfully Completes Statement of Work for BioPharma Company, LexaGene Closes Secured Convertible Note Transaction, Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation. Provides Update on Biopharma Sector, LexaGene Says MiQLab System Detects Mycoplasma at Minute Levels, Gets "Additional Interest" from BioPharma Customers, LEXAGENE HOLDINGS INC. : Q3 2023 Earnings Release, LexaGene Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022, LexaGene Gains as Engaged by BioPharma Firm in Second Feasibility Study; Cancels Plan to Reprice Meridian's Warrants, Lexagene Holdings Inc. Brief: Up 21% Early Friday As BioPharma Engages it in Second Feasibility Study; LXG Cancels Plans to Reprice Meridian's Warrants, LexaGene Successfully Completes Statement of Work for BioPharma Company, LexaGene Holdings Inc. announced that it has received $1.6 million in funding from Meridian LGH Holdings 2, LLC, LexaGene Says Large Biopharma Co Engages It in Statement of Work to Expedite Technology Validation, LexaGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022, LexaGene Rises 23% as Says Got Signed Quote from Large Biopharma Company to Buy a MiQLab System, LexaGene Says Received Signed Quote from Large Biopharma Company to Buy a MiQLab System, LexaGene Holdings Inc. Receives Signed Quote from Large Biopharma Company to Purchase A MiQLab System, LexaGene's MiQLab System Generates Leptospira Results in 30 minutes Using Isothermal Chemistry, LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 Minutes Using Isothermal Chemistry, LexaGene Says U of Penn's School of Veterinary Medicine to Evaluate New Gastrointestinal Panel With MiQLab System, Lexagene Holdings Inc. Reduces Time-To-Result by 35%, LexaGene Holdings Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022, LexaGene Holdings Completes Multi-Center Validation Study Using MiQLab System for Diagnosing Urinary Tract Infections, LexaGene Holdings Inc. Completes Multi-Center Validation Study Using MiQLab System for Diagnosing Urinary Tract Infections, LEXAGENE HOLDINGS INC. : FY 2022 Earnings Release, LexaGene Holdings Inc. Romaine Bostick breaks down the day's top stories and trading action leading into the close. The second tranche will comprise 5,384,275 units issued at the issue price per unit for gross proceeds of $1,884,496.25 (Canadian) (approximately $1,453,754.25 (U.S.)). The company said it intends to use the proceeds of the private placement towards purchasing inventory for manufacturing more MiQLabSystems, supporting sales, marketing, and continued R&D. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Find a Location. Assuming the exercise of all of the Warrants and the conversion of the entire US$1,300,000 principal amount outstanding under the Note (and assuming no accrued and unpaid interest on the Note), Meridian would, indirectly, own and exercise control over 44,647,059 Common Shares, representing approximately 27.08% of the Issuer's issued and outstanding Common Shares (on a post-exercise and post-conversion basis). Curt Boisfontaine, the manager of Meridian LGH Holdings and Meridian Veterinary Capital, stated: "Meridian has sponsored many investments in the veterinary field. Jon has been reporting on stock markets for almost thirty years for newspapers, newswires, and websites. Meridian Realty Advisors is part of the Real Estate industry, and located in Texas, United States. Expand Search Menu. Learn More. In addition, on November 1, 2022, the Issuer issued, to Meridian Holdings II, on a private placement basis, a senior convertible note (the "Note") for an aggregate principal amount of up to US$1,600,000 and bearing interest at a rate of 12% per annum (or 16% in the event of a default). Read More LexaGene Holdings Proposes to Amend Warrants Terms October 27, 2022 The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately two hours. Nothing? Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Data delayed 15 minutes unless otherwise indicated. Iran Brings Back Morality Police Patrol to Enforce Hijab Law, Former BNY Mellon Executive Says He Was Fired for Aiding Friends Complaint, Tropical Storm Calvin Is Churning Toward Hawaiis Big Island, New York Citys Air Quality Unhealthy for Sensitive Groups, Bikeshare Is Still Growing in Popularity After Pandemic CyclingBoom, NY MTAs Budget Gap to Grow to $918 Million by 2029, Watchdog Says. LexaGene Holdings ( OTCQB:LXXGF) has filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code. The first tranche consisted of 13,115,725 units priced at C$0.35 per unit (approximately US$0.27 per unit) for gross proceeds of C$4,590,503.75 (approximately US$3,541,245.75), bringing the total investment to nearly $6.5 million. LexaGene said it intends to use the proceeds of the private placement towards purchasing inventory for manufacturing more MiQLabSystems, supporting sales, marketing, and continued R&D. USA February 08, 2022 LexaGene Holdings, Inc.,(OTCQB: LXXGF;TSX-V: LXG) (LexaGene or the Company),amolecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce that Meridian LGH Holdings LLC, (the Investor) has agreed to make an investment in LexaGene for a total of CAD$6,475,000 (approximately USD$4,995,000). The company and the investor intend that the investment will occur by way of non-brokered private placement anticipated to close in two tranches. Important factors including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues that could cause actual results to differ materially from the Companys expectations as disclosed in the Companys documents filed from time to time on SEDAR (see www.sedar.com). Lancaster General Hospital. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. This is content that excites and engages motivated private investors. Amid the Crypto Crackdown? We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Toggle navigation OPEN GOV US Israel Quietly Embeds AI Systems in DeadlyMilitary Operations, Starmer Faces UK Labour Backlash Over Bid for Fiscal Restraint, Morocco Says Israel Backs Claim to Disputed African Territory, Marriott Aimsfor Las Vegas Strip With MGM Resorts Loyalty Pact, Harlan Crows Real Estate Empire Is Thriving Despite Supreme Court Controversy, The 13 Best Sunscreens for Every Need, From Mineral to Kid-Friendly, How to Make the Most of Flying Economy, FromLondons Premier Fixer, Biden DeploysPentagon to Beat Climate Change and China, The Hard Work on Casino Has Barely Even Begun, Stocks Took an 18-Month Round Trip From Tech Bear to AI Bull. The principal amount outstanding under the Note is convertible into Common Shares at a price of US$0.17 (C$0.23) and any accrued and unpaid interest is convertible into Common Shares at the last closing price (in US dollars) of the Common Shares on the TSX-V on the day prior to the issuance of a news release announcing such conversion. Based in Dallas, Tex., the investor is a subsidiary of Meridian Veterinary Capital LLC. Lexagene said it intends to use the proceeds to purchase inventory to manufacture more MiQLab Systems, supporting sales, marketing, and continued R&D, East Side Games Group is creating engaging games for mobiles from IPs that produce enduring player loyalty, Noble reiterates Outperform rating for Newrange Gold as drilling kicks off at its North Birch projects in Ontario, Electra Battery Materials is advancing Canadian cobalt refinery to serve the rapidly expanding North American EV supply chain, American Resources supplying high-quality raw materials to the new infrastructure market, GoviEx Uranium, the Africa-focused uranium company, continues to de-risk its large resource base, Steppe Gold building Mongolia's premier precious metals group and progressing ATO mine expansion plans, Trillion Energy International is quickly becoming an energy powerhouse in Eastern Europe, Nova Minerals ramps up exploration at Estelle Gold Project in prolific region of Alaska, Plurilock Security is locked in to rapid organic and M&A growth, Victory Battery Metals shores up mining interests in North America, advances Loner Project in Nevada and Canadian assets, TNR Gold is building a new kind of royalty company, Century Lithium progressing an advanced-stage lithium project in Nevada towards feasibility, Nextech3D.AI seeing rapid growth as augmented reality goes mainstream, Canada Silver Cobalt Works aiming to be a big player in Canada's heartland for the two metals, and targeting EV battery market, MGC Pharmaceuticals to accelerate clinical pipeline development, ioneer's Rhyolite Ridge lithium-boron project in US poised to take advantage of global shift toward sustainable energy solutions, HighGold Mining continuing to advance a "great deposit" at Johnson Tract, Alaska, Talon Metals advancing exciting Tamarack project, one of the US's only undeveloped nickel projects, Cabral Gold continuing to find gold targets at Cui Cui project in north-eastern Brazil, LexaGene Holdings Inc (TSX-V:LXG, OTCQB:LXXGF), READ:LexaGene says Meridian LGH agrees to make an investment totaling C$6,475,000 in the company. USA - November 1, 2022 - LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or the "Company"), a molecular diagnostics company that has commercialized the MiQLab System for automated multiplex PCR testing, announces that it has issued a 12% secured convertible note (the "Note") to Meridian LGH Holdings 2, LLC, an affiliate of an insider of the . If you are in need of enterprise level search, please consider signing up for a Bizapedia Pro Search account as described on this page. Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, Sign up to receive alerts and news direct to your inbox. NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. As a life-long pet owner, Ive owned pets that have suffered from improper diagnosis on drug-resistant infections and Im convinced LexaGenes technology can significantly improve the speed and quality of care veterinarians are able to provide at the point of care. LexaGene Holdings (LXG) has closed the second tranche of its strategic private placement to Meridian LGH Holdings. The second tranche will be comprised of 5,384,275 units issued at the same issue price per unit for gross proceeds of C$1,884,496.25 (approximately US$1,453,754.25). On February 24, 2023, LexaGene Holdings Inc. (the "Company") filed for liquidation under Chapter 7 of Title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Massachusetts (the " Bankruptcy Court "), located in Boston, Massachusetts. Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. Hybrid Hearing Will Be Held 5/11/2023 at 10:00 AM before the Hon. The MiQLabsystem delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. All Rights Reserved - Proactive North America Inc., Proactive Investors LLC. Terms of use. The company and the investor intend that the investment will occur by way of non-brokered private placement anticipated to close in two tranches. Lexagene said it intends to use the proceeds to purchase inventory to manufacture more MiQLab Systems, supporting sales, marketing, and continued R&D. Disclosure of Compensation of Attorney Jonathan Horne in the amount of $23679. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense.